MM
Insider
Marlio Charles Mosseri
10% ownerMarlio Charles Mosseri (10% owner) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales, 1 filed past the two-business-day deadline), most often in Nuvectis Pharma, Inc. (NVCT). Across 2 priced purchase filings, the average 21-session return was -0.0% from execution and +6.0% from disclosure (delay-adjusted; derived). The largest single filing was $957K of NVCT (154,770 sh across 3 lots, as filed), executed Oct 23 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-0.0%
avg across 2 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+6.0%
same 2 filings, from disclosure
Filings, ttm
2
2 buys · 0 sells · 1 late
Median delay
4d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$1.9M
shares × price, as filed
Last traded
Jun 30
Filed Jul 1
Median ADV $5.8M across their filed names
Impact on $10,000 · 12M
$10,980 (+9.8%)
S&P 500 $11,725 (+17.2%) · 7.4 pts behind
Marlio Charles Mosseri
S&P 500
Compounded across filings from disclosure dates · past 12 months
Open performance→Volume by month
Buys $3.6M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
NVCT
Nuvectis Pharma, Inc.
NVCT · 6 buys · 0 sells
6 filings
Recent filings
NVCTPURCHASE
Nuvectis Pharma, Inc.
View filing →
$916K50,000 sh × $18.32
Exec Jun 30
Filed Jul 1 · 1:41 PM ET NVCTPURCHASE Nuvectis Pharma, Inc. View filing → $957K
154,770 sh across 3 lots
Exec Oct 23 2025
Filed Oct 29 2025 · 8:00 AM ET † NVCTPURCHASE Nuvectis Pharma, Inc. View filing → $226K
28,043 sh × $8.05
Exec Jun 18 2025
Filed Jun 20 2025 · 5:30 PM ET NVCTPURCHASE Nuvectis Pharma, Inc. View filing → $172K
21,167 sh × $8.11
Exec May 12 2025
Filed May 13 2025 · 5:30 PM ET NVCTPURCHASE Nuvectis Pharma, Inc. View filing → $1.2M
240,000 sh × $5.00
Exec Feb 7 2025
Filed Feb 11 2025 · 5:30 PM ET NVCTPURCHASE Nuvectis Pharma, Inc. View filing → $149K
32,121 sh × $4.64
Exec Dec 12 2024
Filed Dec 16 2024 · 5:30 PM ET